C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer-Reference-Cited by-同舟云学术

C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer

Published:2016-01 Issue:1 Volume:45 Page:110-116
ISSN:0885-3177
Container-title:Pancreas
language:en
Short-container-title:

Author:

Mitsunaga Shuichi,Ikeda Masafumi,Shimizu Satoshi,Ohno Izumi,Takahashi Hideaki,Okuyama Hiroyuki,Ueno Hideki,Morizane Chigusa,Kondo Shunsuke,Sakamoto Yasunari,Okusaka Takuji,Ochiai Atsushi

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Endocrinology,Hepatology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference23 articles.

1. Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia.;Fearon;World J Surg,1999

2. Cancer and systemic inflammation: treat the tumour and treat the host.;Roxburgh;Br J Cancer,2014

3. Hallmarks of cancer: the next generation.;Hanahan;Cell,2011

4. STATs in cancer inflammation and immunity: a leading role for STAT3.;Yu;Nat Rev Cancer,2009

5. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study.;Proctor;Eur J Cancer,2011

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fibroblast inhibition by tocilizumab enabled gemcitabine/nab‐paclitaxel rechallenge for pancreatic cancer;Cancer Science;2023-08-21

2. FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study;BMC Cancer;2023-02-21

3. FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: A retrospective observational study;2022-11-09

4. Serum levels of IL-6 and CRP can predict the efficacy of mFOLFIRINOX in patients with advanced pancreatic cancer;Frontiers in Oncology;2022-07-29

5. Defining Models to Classify between Benign and Malignant Adnexal Masses Using Routine Laboratory Parameters;Cancers;2022-06-30